Holen Sie sich die Stockscreener-App
168.31
1.69%
-2.6918
Schlusskurs vom Vortag:
$171.00
Offen:
$170.56
24-Stunden-Volumen:
664.28K
Relative Volume:
0.58
Marktkapitalisierung:
$10.21B
Einnahmen:
$4.09B
Nettoeinkommen (Verlust:
$-404.84M
KGV:
-24.95
EPS:
-6.7469
Netto-Cashflow:
$1.24B
1W Leistung:
-0.77%
1M Leistung:
-0.81%
6M Leistung:
+43.26%
1J Leistung:
+37.25%
1-Tages-Spanne:
$167.00
$171.51
1-Wochen-Bereich:
$165.01
$171.70
52-Wochen-Spanne:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
167.95 | 10.39B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.51 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.20 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.28 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Dip Buying: Why is Jazz Pharmaceuticals plc stock going upEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Lmcg Investments LLC Trims Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Mood: Will Jazz Pharmaceuticals plc benefit from green energy policiesTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration - Yahoo Finance
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
JAZZJazz Pharmaceuticals Plc Latest Stock News & Market Updates - Stock Titan
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz sells priority review voucher for $200 million - First Word Pharma
JAZZ: Sharpened rare disease focus, record growth, and pivotal zanidatamab results drive future milestones - TradingView — Track All Markets
JAZZ: Rare disease focus, record revenues, and zanidatamab's breakthrough in GEA drive future growth - TradingView — Track All Markets
JAZZ: Refined rare disease focus, strong 2025 results, and new launches drive future growth - TradingView — Track All Markets
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals PLC $JAZZ Holdings Lessened by Polaris Capital Management LLC - MarketBeat
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham - Yahoo Finance
Jazz Pharmaceuticals stock price target raised to $263 from $247 at BofA - Investing.com Nigeria
Jazz Pharmaceuticals stock price target raised to $230 by Truist Securities - Investing.com Nigeria
Jazz Pharmaceuticals (JAZZ): Truist Securities Boosts Price Targ - GuruFocus
Truist Financial Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - MarketBeat
Jazz Pharmaceuticals plcExpects to meet 2025 revenue guidanceSEC filing - marketscreener.com
Jazz Pharmaceuticals PLCExpects To Meet 2025 Revenue GuidanceSEC Filing - TradingView — Track All Markets
Jazz Pharmaceuticals stock price target raised to $235 by Needham - Investing.com Nigeria
Boehringer and Jazz to test HER2-positive breast cancer combo therapy - Investing.com UK
Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer - The Manila Times
What Analysts Are Saying About Jazz Pharmaceuticals Stock - Benzinga
Needham Raises Price Target for Jazz Pharmaceuticals (JAZZ) to $235 | JAZZ Stock News - GuruFocus
Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain - Yahoo Finance
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year? - simplywall.st
Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval - MSN
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates - sharewise.com
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology (NASDAQ:JAZZ) - Seeking Alpha
Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 - MarketBeat
Jazz Pharmaceuticals (JAZZ) Is Down 5.7% After Strong Ziihera Phase 3 DataHas The Bull Case Changed? - simplywall.st
Lecap Asset Management Ltd. Buys Shares of 6,319 Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by MassMutual Private Wealth & Trust FSB - MarketBeat
Robeco Institutional Asset Management B.V. Cuts Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Why Jazz Pharmaceuticals plc stock remains resilient2025 Earnings Impact & Daily Chart Pattern Signals - ulpravda.ru
What sentiment indicators say about Jazz Pharmaceuticals plc stockJuly 2025 WrapUp & Technical Confirmation Trade Alerts - ulpravda.ru
Jazz pharmaceuticals appoints Thomas Riga as chief business officer By Investing.com - Investing.com South Africa
Jazz pharmaceuticals appoints Thomas Riga as chief business officer - Investing.com
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer - StreetInsider
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer - marketscreener.com
Should I hold or sell Jazz Pharmaceuticals plc stock in 2025Weekly Trend Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results - simplywall.st
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):